Clinical Trials Logo

Clinical Trial Summary

Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease, belonging to the wide spectrum of spondyloarthritis, but with the particularity to be associated with personal psoriasis or familial psoriasis. PsA can be a very disabling disease through progressive and irreversible joint damage. Long-term functional prognosis of patients with PsA is correlated with the presence and severity of the radiographic joint lesions of the disease. However, the proportion of patients who will develop those peripheral joint damages is not yet known and less over the factors which are associated/involved in such an aggressive pattern of the disease. Early identification of this subgroup of patients is particularly important for determining early "intensive" treatment, strict management with a Treat To Target approach, and identification of new treatments with a stronger structural effect. The main objective of this prospective 10 years cohort is to describe the 5 years structural (radiographic) severity of recent PsA with recent peripheral arthritis.Some of the secondary objectives are to describe the 10 years structural severity within those patients, and to determine the predictive factors of those 5 and 10 years radiographic lesions (genetic, environmental, clinic, therapeutic factors). APACHE will provide a unique longitudinal standardized database concerning patients with PsA with very recent peripheral arthritis. Research projects which will based on those collected data should allow to identify the mechanisms of aggressive joint damage, to highlight mew treatments targets, to better describe the burden of the disease, to test previous or develop new assessments tolls, to develop early diagnostic criteria


Clinical Trial Description

Method:APACHE is a prospective national multicentre (29) cohort including and following during 10 years patients with a first peripheral arthritis in the past year, attributing to a PsA according to the treating rheumatologist. 425 patients will be included during a 4 years period before the follow-up. Standardized visits are planned throughout the 10 years follow-up, permitting the collection of various data: - clinical data - Patients Reported Outcome - usual lab parameters - plasma, serum and urines - Baseline and one year RNA, DNA - peripheral X-Rays, Ultrasounds and MRI at different time points Those visits have non interventional character (no therapeutic decision will be taken) Those collected data will allow submissions of many research projects to the scientific committee of the cohort. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03768271
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Pascal CLAUDEPIERRE, PHD
Phone 01 49 81 47 04
Email pascal.claudepierre@aphp.fr
Status Recruiting
Phase
Start date February 12, 2020
Completion date March 1, 2034

See also
  Status Clinical Trial Phase
Completed NCT04152759 - Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects Phase 1
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT01925768 - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Phase 3
Completed NCT01892436 - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Phase 3
Completed NCT01212770 - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01212757 - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT03953378 - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting NCT02572700 - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed NCT02556034 - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02188654 - Metformin in Psoriatic Arthritis N/A
Completed NCT02164214 - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Phase 3
Completed NCT01392326 - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Phase 3
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4
Completed NCT00659412 - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis Phase 2
Completed NCT00946686 - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions Phase 1
Not yet recruiting NCT06059430 - Cohort Project of Patients With Inflammatory Rheumatism